ASP3026 – 5 mg

Brand:
Cayman
CAS:
1097917-15-1
Storage:
-20
UN-No:
Non-Hazardous - /

ASP3026 is an ATP-competitive, second-generation ALK inhibitor (IC50 = 3.5 nM) that also inhibits ROS (IC50 = 8.9 nM) and ACK (IC50 = 5.8 nM).{29825,29756} It inhibits neuroblastoma-activating ALK mutants F1174L (IC50 = 10 nM) and R1275Q (IC50 = 5.4 nM) and demonstrates antitumor activity in xenograft mouse models.{29825,29756} ASP3026 has been shown to overcome crizotinib (Item No. 12087) resistance in non-small cell lung cancer, and is currently being evaluated in clinical trials of patients with ALK-positive solid tumors.{29756}  

 

Available on backorder

SKU: - Category:

Description

An ATP-competitive, second-generation ALK inhibitor (IC50 = 3.5 nM) that also inhibits ROS (IC50 = 8.9 nM) and ACK (IC50 = 5.8 nM); demonstrates antitumor activity in xenograft mouse models and has been shown to overcome crizotinib resistance in non-small cell lung cancer


Formal name: N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine

Synonyms: 

Molecular weight: 580.7

CAS: 1097917-15-1

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|Other Receptor Tyrosine Kinases||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling